The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

Cushing’s syndrome survivor and public health advocate ... Fari called on President Bola Ahmed Tinubu’s administration to invest in rare disease research, strengthen advocacy, and train ...

Cortisol belly’ and ‘cortisol face’ are catchy terms but they oversimplify complex biological processes into insecurities.

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Previously, the treatment had been indicated for Cushing disease, a subtype of Cushing syndrome. Isturisa is a cortisol synthesis inhibitor. By blocking 11-beta-hydroxylase, the enzyme responsible ...